2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2221

Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
Abstract Number: 2222

Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Abstract Number: 2223

Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study
Abstract Number: 2224

Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population
Abstract Number: 2225

Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study
Abstract Number: 2226

Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Abstract Number: 2227

What Should be the Goals of Gout Therapy? a Patient Perspective
Abstract Number: 2228

A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Abstract Number: 2229

Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Abstract Number: 2230

Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Abstract Number: 2231

An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
Abstract Number: 2232

Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Abstract Number: 2233

Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
Abstract Number: 2234

Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Abstract Number: 2235

Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].